Reza Halse, PhD, has over 15 years’ experience in the life sciences industry spanning research and business functions across a broad range of therapeutic areas.
He currently serves as President of Merck’s MRL Ventures Fund and is responsible for its investments in Imago, Lava Therapeutics, LifeMine and Caraway Therapeutics. Previously, Dr. Halse led business development and licensing in Europe for MRL. As a corporate venture capital investor, he has previously managed investments in a number of life sciences companies, including: Adheron (acquired by Roche 2015); Editas (NASDAQ: EDIT); LTI Therapeutics; miRagen (NASDAQ:MGEN); Spero (NASDAQ:SPRO); and Visterra (acquired by Otsuka 2018).
Prior to MRLV, he was a partner with the Partners Innovation Fund, which is the corporate venture capital arm of Partners HealthCare, an academic medical center and Harvard Medical School affiliate. He has also held management roles in large pharmaceutical and private life sciences companies in both the United Kingdom and United States.
Dr. Halse holds a Bachelor of Science in biochemistry and a doctorate degree in cell biology from Newcastle University in the UK.